Drugs / BCMA CAR-T

Trials 15 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 05 trials
Phase 0 NCT07435779 Feb 2026 → Feb 2027 expected Hebei Senlang Biotechnology Inc., Ltd. Recruiting No outcome recorded
Phase 0 NCT06791681 Jan 2025 → Nov 2027 expected refractory plasma cell neoplasm Chunrui Li Recruiting No outcome recorded
Phase 0 NCT06681337 Nov 2024 → Dec 2025 overdue lupus nephritis Bioray Laboratories Not yet recruiting No outcome recorded
Phase 0 NCT06691685 Nov 2024 → Nov 2027 expected plasma cell myeloma Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Recruiting No outcome recorded
Phase 0 NCT04626752 Apr 2020 → Mar 2023 refractory plasma cell neoplasm Hebei Senlang Biotechnology Inc., Ltd. Unknown No outcome recorded
Phase 1/22 trials
Phase 1/2 NCT07109323 Mar 2025 → Mar 2028 expected extramedullary soft tissue plasmacytoma, plasma cell leukemia, refractory plasma cell neoplasm Institute of Hematology & Blood Diseases Hospital, China Recruiting No outcome recorded
Phase 1/2 NCT03322735 Dec 2017 → Oct 2018 plasma cell myeloma Henan Cancer Hospital Unknown No outcome recorded
Phase 24 trials
Phase 2 NCT07106710 Aug 2025 → Aug 2027 expected plasma cell myeloma Institute of Hematology & Blood Diseases Hospital, China Recruiting No outcome recorded
Phase 2 NCT07106736 Aug 2025 → Aug 2027 expected plasma cell myeloma Institute of Hematology & Blood Diseases Hospital, China Recruiting No outcome recorded
Phase 2 NCT07106684 Aug 2025 → Aug 2027 expected plasma cell leukemia Institute of Hematology & Blood Diseases Hospital, China Recruiting No outcome recorded
Phase 2 NCT06581640 Sep 2024 → Dec 2028 expected plasma cell myeloma, refractory plasma cell neoplasm The First Affiliated Hospital of Xiamen University Recruiting No outcome recorded
Phase not applicable4 trials
NCT05618041 Sep 2022 → Sep 2027 expected acute lymphoblastic leukemia, plasma cell myeloma Hebei Senlang Biotechnology Inc., Ltd. Recruiting No outcome recorded
NCT03492268 Nov 2021 → Dec 2022 plasma cell myeloma Bioray Laboratories Withdrawn No outcome recorded
NCT04447573 Jun 2020 → Aug 2022 plasma cell myeloma Hebei Senlang Biotechnology Inc., Ltd. Unknown No outcome recorded
NCT03473496 Mar 2018 → Jan 2020 plasma cell myeloma Zhujiang Hospital Terminated No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 15 sources stand behind the page.

FieldValueCited text
Known as BCMA-CART “one kind of BCMA-CART,CD138-CART,CD56-CART or CD38-CART,subjects will receive 10\^6-10\^7/Kg transduced CAR T cells at one time.” NCT03473496
12

“autologous BCMA CAR-T transfusion” NCT06581640

“BCMA CAR-T” NCT05618041

NCT03492268

NCT06681337

NCT07109323

NCT03322735

NCT07435779

NCT07106684

NCT04447573

NCT04626752

NCT07106710

NCT07106736

Known as ESO-T01 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06791681
1

NCT06691685

Action Deplete “these CART cells to recognize and kill BCMA-expressing MM tumor cells” NCT03492268
Modality Cell therapy “BCMA CAR-T cells will be administered after completion of the chemotherapy.” NCT03322735
Route Other “BCMA CAR-T cell infusion” NCT06581640